Melior Discovery, Inc. is a private biopharmaceutical company based in Exton, Pennsylvania, USA.

The company specializes in drug repositioning and has established a proprietary phenotypic screening platform that it uses for this purpose.

Melior also offers certain contract research organization (CRO) services comprising animal models representing different disease conditions.

[citation needed] The Company has issued press releases disclosing partnerships with Pfizer, Merck & Co., Johnson & Johnson, and AstraZeneca, all citing the use of the company's drug repositioning technology.

[5] In June 2016, the company reported positive results from their Phase 2a clinical study in diabetic subjects.